{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:32Z","timestamp":1793431952687,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtos.2024.03.008","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T02:57:00Z","timestamp":1710817020000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["New-onset keratitis associated with epidermal growth factor receptor-based targeted therapies in Han Chinese patients with lung cancer: A multi-center cohort study"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-4144","authenticated-orcid":false,"given":"Kevin Sheng-Kai","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-En","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chodosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Dana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2024.03.008_bib1","first-page":"1","article-title":"EGFR-mediated cell cycle regulation","volume":"22","author":"Lui","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtos.2024.03.008_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2024.03.008_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib5","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","article-title":"Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting System","volume":"10","author":"Huang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtos.2024.03.008_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","article-title":"Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors","volume":"18","author":"Lenihan","year":"2013","journal-title":"Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","article-title":"Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer","volume":"88","author":"Takeda","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtos.2024.03.008_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/15569527.2010.498398","article-title":"Epidermal growth factor receptor in corneal damage: update and new insights from recent reports","volume":"30","author":"Marquez","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jtos.2024.03.008_bib10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtos.2024.03.008_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-019-1285-9","article-title":"Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors","volume":"20","author":"Shin","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jtos.2024.03.008_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920907543","article-title":"Corneal side effects induced by EGFR-inhibitor antibody-drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study","volume":"12","author":"Parrozzani","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.actbio.2015.11.042","article-title":"Preservation of human limbal epithelial progenitor cells on carbodiimide cross-linked amniotic membrane via integrin-linked kinase-mediated Wnt activation","volume":"31","author":"Ma","year":"2016","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jtos.2024.03.008_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s13287-021-02564-7","article-title":"Long-term survival of cultivated oral mucosal epithelial cells in human cornea: generating cell sheets using an animal product-free culture protocol","volume":"12","author":"Ma","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jtos.2024.03.008_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/srep36266","article-title":"Preservation of epithelial progenitor cells from collagenase-digested oral mucosa during ex vivo cultivation","volume":"6","author":"Hsueh","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtos.2024.03.008_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1188\/16.ONF.235-243","article-title":"Ocular toxicity of tyrosine kinase inhibitors","volume":"43","author":"Davis","year":"2016","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.jtos.2024.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2023.1137637","article-title":"Ocular surface complications following biological therapy for cancer","volume":"5","author":"Ma","year":"2023","journal-title":"Front Toxicol"},{"key":"10.1016\/j.jtos.2024.03.008_bib20","first-page":"1","article-title":"Epidermal growth factor receptor inhibitors for lung cancer and the risk of keratitis","author":"Huang","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jtos.2024.03.008_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jtos.2021.06.010","article-title":"Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome\/toxic epidermal necrolysis in cancer patients","volume":"22","author":"Ma","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2024.03.008_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/bjophthalmol-2020-317105","article-title":"Human leucocyte antigen association of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications in Han Chinese","volume":"106","author":"Ma","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.03.008_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtos.2024.03.008_bib22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtos.2024.03.008_bib23","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2024.03.008_bib24","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12032-012-0349-y","article-title":"Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis","volume":"30","author":"Yoshida","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib26","article-title":"Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: a meta-analysis","volume":"15","author":"Choi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2024.03.008_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ctrv.2018.06.018","article-title":"Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer","volume":"69","author":"Sharma","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtos.2024.03.008_bib28","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2024.03.008_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting System (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005886","article-title":"Epidermal EGFR controls cutaneous host defense and prevents inflammation","volume":"5","author":"Lichtenberger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtos.2024.03.008_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0014-4835(03)00202-1","article-title":"Interaction of EGF family growth factors and neurotransmitters in regulating lacrimal gland secretion","volume":"78","author":"Dartt","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2024.03.008_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1470-2045(09)70110-X","article-title":"EGFR testing in lung cancer is ready for prime time","volume":"10","author":"Hirsch","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtos.2024.03.008_bib35","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2024.03.008_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T04:36:51Z","timestamp":1718253411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012424000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":35,"alternative-id":["S1542012424000387"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2024.03.008","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New-onset keratitis associated with epidermal growth factor receptor-based targeted therapies in Han Chinese patients with lung cancer: A multi-center cohort study","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2024.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}